Page 1Page 1

HIV Self-testing in global and UNITAID

strategy

Carmen Pérez-CasasUNITAID

27, February, 2015BMGF

Page 2

HIV-Monitoring

By 2020: 90% of people on ART virally supressed Current: < 30% access viral load

HIV-Treatment

By 2020: 90% of HIV-infected people on ART Current: 38% (24% for children)

HIV-Testing

By 2020: 90% of people know their HIV status Current: 50% (42% in children)

HIV PreventionBy 2030: 75% reduction in new infections, zero new infant infections

Current: 2.1 m infected in 2013 (11,4% children)

Increased testing, key for targets achievement

Page 3

Investment on Self-testing within current HIV UNITAID portfolio

HIV-Monitoring MSF-CD4*/VL ($28.6m)

CHAI/UNICEF-CD4*/VL ($35m)

FEI- VL ($6.2m)

Market entry projects: DRW VL ($8.4m), Daktari CD4* ($2.56m), Burnett CD4* ($1.6m); Wave 80 VL ; Cavidi VL ; MGH –TDF RDT

HIV-Treatment DNDi-Paediatric ARVs($17.3 m)

CHAI- Paediatric ARV market ($12.6 m)

Tides-Access to ARVs for MICs ($6m)

Medicines Patent Pool (current extension $29m)

HIV-TestingEGPAF Early Infant Diagnosis ($63m)

Market entry: NWGHF ($3,7m); DRW ($8.4 m EID/VL)

EID components in CHAI/UNICEF & MSF projects

PSI Self-testing($23 m for Phase I)

HIV PreventionNeed to increase number of people linked with prevention care (e.g. VMC and ARV-prevention methods such as PrEP) and with HIV care

(e.g. ART, also decreasing transmission rates)

Contribution to overarching projects, cofunding with other donors (BMGF): WHO prequalification programe

(current extension for medicines $38m; diagnostic and devices $12m)

Page 4

All areas of cascade show market deficiencies; severe market shortcomings for diagnostic tools

http://www.unitaid.eu/en/unitaid-market-dynamics-dashboard

Case for UNITAID‐support: Robust case made for UNITAID funding before general scale‐up of 

the product and model can take place;  High potential for public health impact and value for money by 

decreasing current testing gap  (complementing current models); Market effects could be delayed (price reduction, adaptability of 

products for use in LMICs, quality assured suppliers) in the absence of this timely investment. 

Stimulating and shaping the market for HIV self-testing in Africa

UNITAID/PSI HIV STAR Project (UCL, LSTM, LHSTM and WHO)

THANK YOU FOR YOUR ATTENTION